Raf kinases in lung tumor development

Advances in Enzyme Regulation

Volumn 43, Issue 1, 2003, Pages 183-195

  Rapp, Ulf R ^a   Fensterle, Joachim ^a   Albert, Stefan ^a   Götz, Rudolf ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 0037702247     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(03)00002-5     Document Type: Conference Paper

References (66)

1. Aubin J, Lemieux M, Tremblay M, Berard J, Jeannotte L. Early postnatal lethality in Hoxa-5 mutant mice is attributable to respiratory tract defects. Dev Biol 1997;192:432-45.
2. Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp UR, Wirth T. Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci USA 2000;97:4615-20.
3. Bermudes D, Low B, Pawelek J. Tumor-targeted Salmonella. Highly selective delivery vectors. Adv Exp Med Biol 2000;465:57-63.
4. Bosslet K, Schirrmacher V. Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes. J Exp Med 1981;154:557-62.
5. Cook SJ, McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science 1993;262:1069-72.
6. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 2001;98:15155-60.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
8. Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol 2002;22:3237-46.
9. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;24:24.
10. Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature 2002;418:790-3.
11. Ehl S, Hombach J, Aichele P, Rulicke T, Odermatt B, Hengartner H, Zinkernagel R, Pircher H. Viral and bacterial infections interfere with peripheral tolerance induction and activate CD8+ T cells to cause immunopathology. J Exp Med 1998;187:763-74.
12. Erhardt P, Troppmaier J, Rapp UR, Cooper GM. Differential regulation of Raf-1 and B-Raf and Ras-dependent activation of mitogen-activated protein kinase by cyclic AMP in PC12 cells. Mol Cell Biol 1995;15:5524-30.
13. Fedorov LM, Tyrsin OY, Papadopoulos T, Camarero Calderón G, Götz R, Rapp UR. Bcl-2 determines susceptibility to induction of lung cancer by oncogenic CRaf. Cancer Res 2002;62:6297-303.
14. Federov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Rapp UR. Loss of p53 in craf induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch. Cancer Res (in press).
15. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997;88:435-7.
16. Gentschev I, Mollenkopf HJ, Sokolovic Z, Ludwig A, Tengel C, Gross R, Hess J, Demuth A, Goebel W. Synthesis and secretion of bacterial antigens by attenuated Salmonella via the Escherichia coli hemolysin secretion system. Behring Inst Mitt 1994:57-66.
17. Gentschev I, Mollenkopf H, Sokolovic Z, Hess J, Kaufmann SHE, Goebel W. Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway. Gene 1996;179:133-40.
18. Gentschev I, Dietrich G, Goebel W. The E. coli α-hemolysin secretion system and its use in vaccine development. Trends Microbiol 2002;10:39-45.
19. Gould A. Functions of mammalian Polycomb group and trithorax group related genes. Curr Opin Genet Dev 1997;7:488-94.
20. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+T cells. J Exp Med 1996;184:19-29.
21. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 1999;253:34-46.
22. Hekman M, Hamm H, Villar AV, Bader B, Kuhlmann J, Nickel J, Rapp UR. Associations of B- and C-Raf with cholesterol, phosphatidylserine, and lipid second messengers: preferential binding of Raf to artificial lipid rafts. J Biol Chem 2002;277:24090-102.
23. Herrera R, Sebolt-Leopold JS. Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 2002;8:S27.
24. Hess J, Gentschev I, Miko D, Welzel M, Ladel C, Goebel W, Kaufmann SHE. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA 1996;93:1458-63.
25. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
26. Hong KU, Reynolds SD, Giangreco A, Hurley CM, Stripp BR. Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. Am J Respir Cell Mol Biol 2001;24:671-81.
27. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
28. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002;14:178-82.
29. Kaufmann SH. Cell-mediated immunity: dealing a direct blow to pathogens. Curr Biol 1999;9:R97-9.
30. Kaufmann SHE, Fensterle J, Hess J. The need for a novel generation of vaccines. Immunobiology 1999;201:272-82.
31. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 2000;11:185-90.
32. Kerkhoff E, Simpson JC, Leberfinger CB, Otto IM, Doerks T, Bork P, Rapp UR, Raabe T, Pepperkok R. The Spir actin organizers are involved in vesicle transport processes. Curr Biol 2001;11:1963-8.
33. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
34. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
35. Liu YZ, Boxer LM, Latchman DS. Activation of the Bcl-2 promoter by nerve growth factor is mediated by the p42/p44 MAPK cascade. Nucleic Acids Res 1999;27:2086-90.
36. Livingston PO, Ragupathi G, Musselli C. Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J Clin Immunol 2000;20:85-93.
37. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.
38. Maryanski JL, Marchand M, Uyttenhove C, Boon T. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Int J Cancer 1983;31:119-23.
39. Moudgil KD, Sercarz EE. The self-directed T cell repertoire: its creation and activation. Rev Immunogenet 2000;2:26-37.
40. Neufeld B, Grosse-Wilde A, Hoffmeyer A, Jordan BW, Chen P, Dinev D, Ludwig S, Rapp UR. Serine/Threonine kinases 3pK and MAPK-activated protein kinase 2 interact with the basic helix-loop-helix transcription factor E47 and repress its transcriptional activity. J Biol Chem 2000;275:20239-42.
41. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999;96:2233-8.
42. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, Hemmi S, Hengartner H, Zinkernagel RM. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001;411:1058-64.
43. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 1997;57:4537-44.
44. Raabe T, Rapp UR. KSR - a regulator and scaffold protein of the MAP kinase pathway. Science's STKE 2002; (www.stke.org/cgi/content/full/sigtrans; 2002/136/pe28).
45. Rapp UR, Troppmair J. Dominant oncogenes as cancer targets: role of raf kinases and myc, two master regulators of phenotypic and genotypic stability. In: Rosenthal R, Wahn U, Wolf H, editors. Einfluss von Genomprojekt und Pharmacogenetics auf die medizinische Entwicklung. Symposium of the Novartis Stiftung. Stuttgart, New York: Schattauer Verlag, 2002. p. 25-42.
46. Rapp UR, Cleveland JL, Storm SM, Beck TW, Huleihel M. Transformation by raf and myc oncogenes. In: Aaronson SA, Bishop J, Sugimura T, Terada M, Toyoshima K, Vogt PK, editors. Oncogenes and Cancer, Proceedings of the 17th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, 1986. Tokyo: Japan Sci Press, Tokyo/VNU Science Press, 1987. p. 55-74.
47. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993;20:105-27.
48. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
49. Rozelle AL, Machesky LM, Yamamoto M, Driessens MH, Insall RH, Roth MG, Luby-Phelps K, Marriott G, Hall A, Yin HL. Phosphatidylinositol 4,5-bisphosphate induces actin-based movement of raft-enriched vesicles through WASP-Arp2/3. Curr Biol 2000;10:311-20.
50. Schirrmacher V, Bosslet K, Shantz G, Clauer K, Hubsch D. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes. Int J Cancer 1979;23:245-52.
51. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000;19:6594-9.
52. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997;387:569-72.
53. Spreng S, Dietrich G, Niewiesk S, ter Meulen V, Gentschev I, Goebel W. Novel bacterial systems for the delivery of recombinant protein or DNA. FEMS Immunol Med Microbiol 2000;27:299-304.
54. Stauss HJ. Benign autoimmunity to combat malignancy. Clin Exp Immunol 2001;125:1-2.
55. Storm SM, Rapp UR. Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. Toxicol Lett 1993;67:201-10.
56. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995;182:477-86.
57. Tait BD. HLA class I expression on human cancer cells. Implications for effective immunotherapy. Hum Immunol 2000;61:158-65.
58. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001;358:489-97.
59. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber D J, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142-52.
60. Urban JL, Kripke ML, Schreiber H. Stepwise immunologic selection of antigenic variants during tumor growth. J Immunol 1986;137:3036-41.
61. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996;87:629-38.
62. Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc Natl Acad Sci U S A 1996;93:7063-8.
63. Wojnowski L, Stancato LF, Zimmer AM, Hahn H, Beck TW, Larner AC, Rapp UR, Zimmer A. Craf-1 protein kinase is essential for mouse development. Mech Dev 1998;76:141-9.
64. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-32.
65. Yang X, Hao Y, Ferenczy A, Tang SC, Pater A. Overexpression of anti-apoptotic gene BAG-1 in human cervical cancer. Exp Cell Res 1999;247:200-7.
66. Zhang BH, Guan KL. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 2000;19:5429-39.